Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection

Lorraine C. Racusen(Johns Hopkins Medicine), Robert B. Colvin(Massachusetts General Hospital), Kim Solez(University of Alberta), Michael J. Mihatsch(University of Basel), Philip F. Halloran(University of Alberta), Patricia Campbell(University of Alberta), Michael Cecka(University of California, Los Angeles), Jean‐Pierre Cosyns(UCLouvain), Anthony J. Demetris(Pittsburg State University), Michael C. Fishbein(University of California, Los Angeles), Agnes B. Fogo(Vanderbilt University), Peter Furness(University of Leicester), Ian W. Gibson(Health Sciences Centre), Denis Glotz(Hôpital Européen Georges-Pompidou), P Häyry(University of Helsinki), Lawrence Hunsickern(University of Iowa), Michael Kashgarian(Yale University), Ronald H. Kerman(The University of Texas Health Science Center at Houston), Alex J. Magil(St. Paul's Hospital), Robert A. Montgomery(Johns Hopkins University), Kunio Morozumi(Nagoya City University), Volker Nickeleit(University of North Carolina at Chapel Hill), Parmjeet Randhawa(Pittsburg State University), Heinz Regele(University of Vienna), Daniel Serón(Universitat de Barcelona), Surya V. Seshan(Cornell University), Ståle Sund(Hospital IT), Kiril Trpkov(Rockyview General Hospital)
American Journal of Transplantation
May 28, 2003
10.1034/j.1600-6143.2003.00072.x
Cited by 1,063Open Access
Full Text

Abstract

Antibody‐mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation. Antibody‐mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.

Related Papers

The Banff 97 working classification of renal allograft pathology
Lorraine C. Racusen, Kim Solez, Robert B. Colvin et al.|Kidney International|1999|3.1k
Capillary deposition of C4d complement fragment and early renal graft loss
Helmut E. Feucht, H. Schneeberger, Günther F. Hillebrand et al.|Kidney International|1993|534
Complement Activation in Acute Humoral Renal Allograft Rejection
A. Bernard Collins, Eveline E. Schneeberger, Manuel Pascual et al.|Journal of the American Society of Nephrology|1999|513
Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease
Paul J. Michaels, Maria L. Espejo, Jon Kobashigawa et al.|The Journal of Heart and Lung Transplantation|2003|388
ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1
Marta Crespo, Manuel Pascual, Nina Tolkoff-Rubin et al.|Transplantation|2001|351